Entrada Therapeutics IncNASDAQ:TRDA
- LAST PRICE19.8200
- TODAY'S CHANGE (%)0.5900 (3.0681%)
- Bid / Lots18.9000/ 2
- Ask / Lots31.6900/ 2
- Open / Previous Close19.2600 / 19.2300
- Day Range
- 52 Week Range
- Volume239,336
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TRDA |
|---|---|---|
| 09:32 ET | 370 | 19.25 |
| 09:35 ET | 140 | 19.028 |
| 09:37 ET | 3639 | 19.21 |
| 09:48 ET | 900 | 19.24 |
| 09:53 ET | 400 | 19.28 |
| 09:55 ET | 100 | 19.355 |
| 09:57 ET | 855 | 19.24 |
| 10:00 ET | 100 | 19.36 |
| 10:02 ET | 1121 | 19.41 |
| 10:06 ET | 100 | 19.33 |
| 10:09 ET | 600 | 19.36 |
| 10:11 ET | 300 | 19.36 |
| 10:13 ET | 100 | 19.36 |
| 10:15 ET | 1700 | 19.28 |
| 10:22 ET | 100 | 19.22 |
| 10:24 ET | 602 | 19.2 |
| 10:26 ET | 100 | 19.17 |
| 10:27 ET | 500 | 19.0916 |
| 10:29 ET | 100 | 19.05 |
| 10:31 ET | 343 | 19.095 |
| 10:33 ET | 100 | 19.04 |
| 10:36 ET | 200 | 19.14 |
| 10:42 ET | 100 | 19.135 |
| 10:44 ET | 200 | 19.05 |
| 10:45 ET | 100 | 19.135 |
| 10:47 ET | 100 | 19.075 |
| 10:49 ET | 100 | 19.12 |
| 10:51 ET | 400 | 19.13 |
| 10:54 ET | 2822 | 19.295 |
| 10:56 ET | 300 | 19.29 |
| 10:58 ET | 193 | 19.3 |
| 11:02 ET | 400 | 19.28 |
| 11:03 ET | 200 | 19.28 |
| 11:05 ET | 300 | 19.31 |
| 11:07 ET | 300 | 19.26 |
| 11:12 ET | 100 | 19.23 |
| 11:14 ET | 100 | 19.22 |
| 11:20 ET | 600 | 19.055 |
| 11:23 ET | 800 | 19.27 |
| 11:25 ET | 100 | 19.2 |
| 11:27 ET | 1086 | 19.22 |
| 11:30 ET | 200 | 19.23 |
| 11:32 ET | 100 | 19.16 |
| 11:34 ET | 100 | 19.27 |
| 11:36 ET | 300 | 19.25 |
| 11:38 ET | 100 | 19.2 |
| 11:39 ET | 100 | 19.2 |
| 11:41 ET | 800 | 19.265 |
| 11:43 ET | 4032 | 19.305 |
| 11:45 ET | 100 | 19.305 |
| 11:48 ET | 200 | 19.285 |
| 11:50 ET | 100 | 19.305 |
| 11:54 ET | 1000 | 19.38 |
| 11:56 ET | 5593 | 19.66 |
| 11:57 ET | 200 | 19.59 |
| 11:59 ET | 219 | 19.47 |
| 12:03 ET | 100 | 19.58 |
| 12:06 ET | 100 | 19.6 |
| 12:08 ET | 800 | 19.56 |
| 12:10 ET | 300 | 19.568 |
| 12:12 ET | 100 | 19.44 |
| 12:14 ET | 100 | 19.44 |
| 12:15 ET | 654 | 19.415 |
| 12:17 ET | 100 | 19.37 |
| 12:21 ET | 100 | 19.35 |
| 12:24 ET | 100 | 19.35 |
| 12:28 ET | 300 | 19.42 |
| 12:30 ET | 100 | 19.42 |
| 12:33 ET | 14700 | 19.425 |
| 12:35 ET | 650 | 19.49 |
| 12:37 ET | 100 | 19.58 |
| 12:46 ET | 14599 | 19.546 |
| 12:50 ET | 500 | 19.6892 |
| 12:51 ET | 20000 | 19.615 |
| 12:53 ET | 100 | 19.615 |
| 12:55 ET | 200 | 19.61 |
| 12:57 ET | 200 | 19.7078 |
| 01:00 ET | 400 | 19.7 |
| 01:02 ET | 100 | 19.49 |
| 01:04 ET | 350 | 19.5 |
| 01:06 ET | 300 | 19.54 |
| 01:08 ET | 100 | 19.55 |
| 01:13 ET | 100 | 19.58 |
| 01:18 ET | 100 | 19.635 |
| 01:20 ET | 2319 | 19.625 |
| 01:22 ET | 100 | 19.56 |
| 01:24 ET | 100 | 19.63 |
| 01:26 ET | 400 | 19.56 |
| 01:27 ET | 100 | 19.625 |
| 01:29 ET | 3897 | 19.72 |
| 01:31 ET | 2000 | 19.67 |
| 01:33 ET | 300 | 19.67 |
| 01:42 ET | 100 | 19.67 |
| 01:45 ET | 100 | 19.67 |
| 01:47 ET | 950 | 19.79 |
| 01:54 ET | 100 | 19.835 |
| 02:00 ET | 3732 | 19.79 |
| 02:02 ET | 400 | 19.705 |
| 02:12 ET | 501 | 19.77 |
| 02:16 ET | 200 | 19.66 |
| 02:18 ET | 200 | 19.56 |
| 02:20 ET | 200 | 19.6076 |
| 02:23 ET | 192 | 19.65 |
| 02:27 ET | 100 | 19.58 |
| 02:30 ET | 1659 | 19.67 |
| 02:32 ET | 109 | 19.75 |
| 02:34 ET | 200 | 19.72 |
| 02:36 ET | 100 | 19.81 |
| 02:39 ET | 100 | 19.745 |
| 02:41 ET | 300 | 19.72 |
| 02:43 ET | 1350 | 19.755 |
| 02:45 ET | 100 | 19.72 |
| 02:48 ET | 100 | 19.72 |
| 02:50 ET | 900 | 19.8 |
| 02:52 ET | 6700 | 19.83 |
| 02:54 ET | 2429 | 19.765 |
| 03:01 ET | 400 | 19.67 |
| 03:03 ET | 200 | 19.665 |
| 03:06 ET | 450 | 19.68 |
| 03:10 ET | 100 | 19.75 |
| 03:14 ET | 100 | 19.73 |
| 03:21 ET | 300 | 19.76 |
| 03:26 ET | 300 | 19.8 |
| 03:28 ET | 107 | 19.8 |
| 03:30 ET | 2018 | 19.79 |
| 03:32 ET | 4194 | 19.865 |
| 03:37 ET | 700 | 19.86 |
| 03:44 ET | 300 | 19.875 |
| 03:46 ET | 200 | 19.8675 |
| 03:50 ET | 100 | 19.88 |
| 03:51 ET | 3173 | 19.79 |
| 03:53 ET | 1339 | 19.86 |
| 03:55 ET | 1000 | 19.88 |
| 03:57 ET | 1210 | 19.935 |
| 04:00 ET | 29623 | 19.82 |
Nov 6, 2024
DJ Entrada Therapeutics Is Maintained at Outperform by Oppenheimer, from 9:19AM ET on Wednesday Nov 06, 2024 by Dow Jones
9:19AM ET on Wednesday Nov 06, 2024 by Dow JonesDJ Entrada Therapeutics Is Maintained at Buy by HC Wainwright & Co., from 7:46AM ET on Wednesday Nov 06, 2024 by Dow Jones
7:46AM ET on Wednesday Nov 06, 2024 by Dow Jones
Nov 5, 2024
*DJ Entrada Therapeutics 3Q Loss/Shr 35c >TRDA, from 7:03AM ET on Tuesday Nov 05, 2024 by Dow Jones
7:03AM ET on Tuesday Nov 05, 2024 by Dow JonesEntrada Therapeutics Reports Third Quarter 2024 Financial Results, from 7:00AM ET on Tuesday Nov 05, 2024 by Dow Jones
7:00AM ET on Tuesday Nov 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Entrada Therapeutics Inc | 741.7M | 12.4x | --- |
Avid Bioservices Inc | 782.1M | -5.4x | --- |
Y-mAbs Therapeutics Inc | 689.9M | -27.6x | --- |
Adaptive Biotechnologies Corp | 858.3M | -4.0x | --- |
Alector Inc | 563.1M | -3.4x | --- |
Regenxbio Inc | 552.9M | -2.2x | --- |
Company Information
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a class of medicines, which engages intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through its proprietary, highly versatile and modular EEV platform (EEV Platform), the Company is building a robust development portfolio of therapeutic candidates. Its first two drug candidates, ENTR-601-44 and VX-670, are in clinical trials. VX-670 for dystrophy type 1 (DM1) is designed to block the triplet repeats in the messenger RNA (mRNA). ENTR-601-44 is in a Phase I clinical trial. The Company also announced the selection of additional clinical candidates within its Duchenne franchise, ENTR-601-45 and ENTR-601-50.
Contact Information
- Headquarters
- One Design Center Place, Suite 17-500BOSTON, MA, United States 02210
- Phone
- 857-305-1825
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Kush Parmar
- President, Chief Operating Officer
- Nathan Dowden
- Chief Executive Officer, Director
- Dipal Doshi
- Chief Financial Officer, Treasurer
- Kory Wentworth
- Director
- Peter Kim
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $741.7M |
|---|---|
Revenue (TTM) | $215.2M |
Shares Outstanding | 37.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $1.59 |
Book Value | $7.25 |
P/E Ratio | 12.4x |
Price/Sales (TTM) | 3.4 |
Price/Cash Flow (TTM) | 12.7x |
Operating Margin | 26.85% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
